Splitomicin

SKU: orb1222950

Description

Splitomicin is a cell-permeable lactone derived from naphthol and known to be a potent selective inhibitor of Sir2 (silent information regulator 2) and HDAC. Splitomicin inhibits the NAD+-dependent deacetylase activity of Sir2 in vitro. It increases the levels of cyclic AMP by inhibiting the activity of cyclic AMP phosphodiesterase, interferes with mobilization of intracellular Ca+2 and ATP release.

Key Properties

• CAS Number: 5690-03-9
• MW: 198.22
• Purity: >98% (HPLC)
• Formula: C₁₃H₁₀O₂
• SMILES: O=C1CCc2c3ccccc3ccc2O1
• Target: PI3K
• Solubility: In Vitro: DMSO : 100 mg/mL (504.49 mM)

Bioactivity

• In Vivo:
  Animal model: C57BL/6 mice aged 12-14 weeks weighing on average 27 g. Dosage: 80 mg/kg. Administration: Intraperitoneal injection every 24 h for 5 days. Result: Increased TF activity in mouse carotid artery as compared with the controls.
• In Vitro:
  Cell Proliferation Assay Cell line: Human breast cancer MCF-7 and lung cancer H1299 cells. Concentration: 10, 33, 100, and 333 μM. Incubation time: 24 hours. Result: Inhibited colony formation in a dose-dependent manner.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Splitomicin

Quick Database Links

Gene Symbol

PI3K